Edition:
United States

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

8.81USD
22 Sep 2017
Change (% chg)

$-0.06 (-0.68%)
Prev Close
$8.87
Open
$8.86
Day's High
$9.00
Day's Low
$8.73
Volume
78,458
Avg. Vol
165,759
52-wk High
$15.01
52-wk Low
$8.70

Select another date:

Thu, Sep 14 2017

Photo

Exclusive: Prosecutors identify Insys founder as unindicted co-conspirator in opioid case

BOSTON U.S. prosecutors have identified Insys Therapeutics Inc's billionaire founder as an unindicted co-conspirator in a case accusing six former executives and managers of participating in a scheme that involved bribing doctors to prescribe a fentanyl-based drug, according to a court document.

Senator reveals results of opioid inquiry into Insys

BOSTON Insys Therapeutics Inc sought to manipulate insurance payment approval for an opioid cancer pain drug called Subsys even if for inappropriate uses, according to a U.S. Senate report on the opioid crisis released on Wednesday.

UPDATE 1-U.S. senator reveals results of opioid inquiry into Insys

BOSTON, Sept 6 Insys Therapeutics Inc sought to manipulate insurance payment approval for an opioid cancer pain drug called Subsys even if for inappropriate uses, according to a U.S. Senate report on the opioid crisis released on Wednesday.

U.S. senator reveals results of opioid inquiry into Insys

BOSTON, Sept 6 Insys Therapeutics Inc sought to manipulate the process to gain insurance payment approval for an opioid cancer pain drug called Subsys even if for inappropriate uses, according to a U.S. Senate report related to the national opioid addiction crisis released on Wednesday.

Insys rejects Arizona AG's claims drugmaker fueled opioid crisis

Insys Therapeutics Inc on Friday disputed the assertion by the Arizona attorney general that it fueled an opioid addiction epidemic in the state by fraudulently marketing a fentanyl-based drug, saying those claims "lack context and factual accuracy."

BRIEF-Insys addresses Arizona Attorney General complaint

* Says continue to cooperate with investigation by Arizona Attorney General Office

Arizona accuses drugmaker Insys of fraudulent opioid marketing

Arizona sued Insys Therapeutics Inc on Thursday, accusing the drugmaker of engaging in a fraudulent marketing scheme aimed at increasing sales of a fentanyl-based cancer pain medicine called Subsys.

UPDATE 1-Arizona accuses drugmaker Insys of fraudulent opioid marketing

Aug 31 Arizona sued Insys Therapeutics Inc on Thursday, accusing the drugmaker of engaging in a fraudulent marketing scheme aimed at increasing sales of a fentanyl-based cancer pain medicine called Subsys.

Arizona accuses Insys of fraudulent opioid marketing scheme

Aug 31 Arizona's attorney general sued Insys Therapeutics Inc on Thursday, accusing the drugmaker of engaging in a fraudulent marketing scheme aimed at increasing sales of a fentanyl-based cancer pain medicine.

Insys agrees to pay $4.45 million to resolve Illinois opioid lawsuit

BOSTON Insys Therapeutics Inc has agreed to pay $4.45 million to resolve a lawsuit by Illinois' attorney general claiming it deceptively marketed an addictive fentanyl-based cancer pain drug for off-label uses.

Select another date: